AKTS
AKTS
Positions held
Your positionsAKTS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
2026-09-09 · Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT
2026-09-09 · Aktis Oncology to Present at Upcoming September Investor Conferences
2026-08-19 · Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
2026-08-19 · Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
2026-08-19 · Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
2026-08-13 · Aktis: Q2 Earnings Snapshot
2026-08-13 · Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Price (daily)
Full chart · RSI · MACD · patterns